Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Innovations in Dry Eye Testing: New Diagnostic Tools
Dry eye disease (DED), also known as keratoconjunctivitis sicca, is one of the most common ophthalmic conditions, affecting hundreds of millions of people worldwide. Recent technological advances and research targeting DED have led to the emergence of new definitions and…
Cequa Shows Positive Phase 4 Results for Dry Eye
Sun Pharmaceutical has shared new Phase 4 clinical trial data, showcasing the efficacy of Cequa (cyclosporine ophthalmic solution) 0.09% in treating dry eye disease (DED). The results reveal that Cequa provides sustained improvements in patients whose symptoms were inadequately managed…
MediPrint Announces Positive Results for Glaucoma Lens
MediPrint Ophthalmics has revealed positive findings from its Phase 2b clinical trial for LL-BMT1, a 3D-printed, drug-eluting contact lens designed to treat mild to moderate glaucoma. These results, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of…
Top 15 International Ophthalmology Congresses in 2024
As the field of ophthalmology continues to advance, a plethora of international congresses offer opportunities for professionals to explore the latest innovations, share insights, and foster collaborations. Here is a comprehensive list of the top 15 international ophthalmology conferences scheduled…
Alcon Launches PRECISION7 One-Week Contact Lens
Alcon has announced the U.S. launch of PRECISION7, a groundbreaking contact lens designed for a convenient one-week replacement cycle. Incorporating the advanced 7-day ACTIV-FLO system, these lenses offer up to 16 hours of comfort and clear vision, even on the…
Tarsus Appoints Dr. Elizabeth Yeu as Chief Medical Officer
Tarsus Pharmaceuticals has announced the appointment of Elizabeth Yeu, MD, as Chief Medical Officer, effective November 4, 2024. Dr. Yeu, an esteemed ophthalmologist with over two decades of clinical and leadership experience, will lead the company’s medical organization and oversee…
Konan Medical Launches objectiveFIELD Visual Analyzer| OBN
Konan Medical USA has officially launched the objectiveFIELD (OFA) visual field analyzer, a new device that enhances visual field testing by utilizing pupillary responses rather than traditional patient-reliant methods. A Breakthrough in Visual Field Testing: The OFA The objectiveFIELD (OFA)…
GenSight: Lumevoq Most Effective for ND4-LHON
GenSight Biologics recently published a meta-analysis focused on assessing the efficacy of various treatments for Leber Hereditary Optic Neuropathy (LHON) due to the MT-ND4 mitochondrial gene mutation, known as ND4-LHON. The study, which appears in Survey of Ophthalmology, represents a…
Genentech: Vabysmo Effective for Diverse DME Patients
Genentech recently announced encouraging one-year results from its phase 4 ELEVATUM study evaluating Vabysmo (faricimab-svoa) for diabetic macular edema (DME) in racially and ethnically underrepresented populations. The findings, presented at the American Academy of Ophthalmology (AAO) 2024 annual meeting in…
FDA Clears HG202 CRISPR Therapy for Wet AMD Trials
The U.S. FDA has granted investigational drug clearance for HG202, a pioneering CRISPR/Cas13Y RNA-editing therapy developed by HuidaGene to treat neovascular (wet) age-related macular degeneration (AMD). This milestone makes HG202 the first CRISPR/Cas13Y RNA-targeting therapy in clinical development and the…